...
search icon
ccxi-img

ChemoCentryx Inc Share Price

CCXI
NMQ
$10.26
+$0.07
(0.69%)
1D
Industry: Biotechnology Sector: Health Care

ChemoCentryx Inc Analyst Forecast

ChemoCentryx Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$3.74B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
516.00
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.23

About ChemoCentryx Inc, Common Stock

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc. more

Industry: BiotechnologySector: Health Care

ChemoCentryx Inc Stock Returns

Time FrameCCXISectorS&P500
1-Week Return-1.51%-1.5%
1-Month Return-1.46%0.6%
3-Month Return-3.94%2.43%
6-Month Return-16.03%6.01%
1-Year Return-9.1%11.48%
3-Year Return-19.46%67.52%
5-Year Return-83.47%35.29%73.75%
10-Year Return178.42%137.42%254.46%

ChemoCentryx Inc Financials

Dec '17Dec '18Dec '19Dec '20Dec '215YR TREND
Total Revenue82.50M42.88M35.95M64.89M32.22M[{"date":"2017-12-31","value":100,"profit":true},{"date":"2018-12-31","value":51.97,"profit":true},{"date":"2019-12-31","value":43.58,"profit":true},{"date":"2020-12-31","value":78.66,"profit":true},{"date":"2021-12-31","value":39.06,"profit":true}]
Cost of Revenue49.49M62.74M70.28M-302.00K[{"date":"2017-12-31","value":70.43,"profit":true},{"date":"2018-12-31","value":89.27,"profit":true},{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":0.43,"profit":true}]
Gross Profit82.50M42.88M36.13M64.89M31.92M[{"date":"2017-12-31","value":100,"profit":true},{"date":"2018-12-31","value":51.97,"profit":true},{"date":"2019-12-31","value":43.79,"profit":true},{"date":"2020-12-31","value":78.66,"profit":true},{"date":"2021-12-31","value":38.69,"profit":true}]
Gross Margin100.00%100.00%100.49%100.00%99.06%[{"date":"2017-12-31","value":99.51,"profit":true},{"date":"2018-12-31","value":99.51,"profit":true},{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":99.51,"profit":true},{"date":"2021-12-31","value":98.58,"profit":true}]
Operating Expenses66.00M83.14M94.25M120.07M162.14M[{"date":"2017-12-31","value":40.71,"profit":true},{"date":"2018-12-31","value":51.28,"profit":true},{"date":"2019-12-31","value":58.13,"profit":true},{"date":"2020-12-31","value":74.05,"profit":true},{"date":"2021-12-31","value":100,"profit":true}]
Operating Income16.49M(40.27M)(58.30M)(55.18M)(129.92M)[{"date":"2017-12-31","value":100,"profit":true},{"date":"2018-12-31","value":-244.16,"profit":false},{"date":"2019-12-31","value":-353.5,"profit":false},{"date":"2020-12-31","value":-334.55,"profit":false},{"date":"2021-12-31","value":-787.72,"profit":false}]
Total Non-Operating Income/Expense2.73M4.61M5.63M(358.00K)(3.67M)[{"date":"2017-12-31","value":48.54,"profit":true},{"date":"2018-12-31","value":81.88,"profit":true},{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-6.36,"profit":false},{"date":"2021-12-31","value":-65.25,"profit":false}]
Pre-Tax Income17.86M(37.97M)(55.49M)(55.36M)(131.75M)[{"date":"2017-12-31","value":100,"profit":true},{"date":"2018-12-31","value":-212.59,"profit":false},{"date":"2019-12-31","value":-310.71,"profit":false},{"date":"2020-12-31","value":-309.96,"profit":false},{"date":"2021-12-31","value":-737.75,"profit":false}]
Income Taxes-----[{"date":"2017-12-31","value":"-","profit":true},{"date":"2018-12-31","value":"-","profit":true},{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true}]
Income After Taxes17.86M(37.97M)---[{"date":"2017-12-31","value":100,"profit":true},{"date":"2018-12-31","value":-212.59,"profit":false},{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true}]
Income From Continuous Operations17.86M(37.97M)(55.49M)(55.36M)(131.75M)[{"date":"2017-12-31","value":100,"profit":true},{"date":"2018-12-31","value":-212.59,"profit":false},{"date":"2019-12-31","value":-310.71,"profit":false},{"date":"2020-12-31","value":-309.96,"profit":false},{"date":"2021-12-31","value":-737.75,"profit":false}]
Income From Discontinued Operations-----[{"date":"2017-12-31","value":"-","profit":true},{"date":"2018-12-31","value":"-","profit":true},{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true}]
Net Income17.86M(37.97M)(55.49M)(55.36M)(131.75M)[{"date":"2017-12-31","value":100,"profit":true},{"date":"2018-12-31","value":-212.59,"profit":false},{"date":"2019-12-31","value":-310.71,"profit":false},{"date":"2020-12-31","value":-309.96,"profit":false},{"date":"2021-12-31","value":-737.75,"profit":false}]
EPS (Diluted)0.36(0.76)(0.97)(0.84)(1.89)[{"date":"2017-12-31","value":100,"profit":true},{"date":"2018-12-31","value":-211.11,"profit":false},{"date":"2019-12-31","value":-269.44,"profit":false},{"date":"2020-12-31","value":-233.33,"profit":false},{"date":"2021-12-31","value":-525,"profit":false}]

ChemoCentryx Inc Ratios

ChemoCentryx Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

CCXI
Cash Ratio 4.32
Current Ratio 4.54
Quick Ratio 4.47

ChemoCentryx Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CCXI
ROA (LTM) -18.55%
ROE (LTM) -46.96%

ChemoCentryx Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CCXI
Debt Ratio Lower is generally better. Negative is bad. 0.44
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.56

ChemoCentryx Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CCXI
Trailing PE NM
Forward PE NM
P/S (TTM) 100.30
P/B 15.81
Price/FCF NM
EV/R 93.62
EV/Ebitda NM
PEG NM

FAQs

What is ChemoCentryx Inc share price today?

ChemoCentryx Inc (CCXI) share price today is $10.26

Can Indians buy ChemoCentryx Inc shares?

Yes, Indians can buy shares of ChemoCentryx Inc (CCXI) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CCXI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of ChemoCentryx Inc be purchased?

Yes, you can purchase fractional shares of ChemoCentryx Inc (CCXI) via the Vested app. You can start investing in ChemoCentryx Inc (CCXI) with a minimum investment of $1.

How to invest in ChemoCentryx Inc shares from India?

You can invest in shares of ChemoCentryx Inc (CCXI) via Vested in three simple steps:

  • Click on Sign Up or Invest in CCXI stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in ChemoCentryx Inc shares
What is ChemoCentryx Inc 52-week high and low stock price?

The 52-week high price of ChemoCentryx Inc (CCXI) is $. The 52-week low price of ChemoCentryx Inc (CCXI) is $.

What is ChemoCentryx Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of ChemoCentryx Inc (CCXI) is

What is ChemoCentryx Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of ChemoCentryx Inc (CCXI) is 15.81

What is ChemoCentryx Inc dividend yield?

The dividend yield of ChemoCentryx Inc (CCXI) is 0.00%

What is the Market Cap of ChemoCentryx Inc?

The market capitalization of ChemoCentryx Inc (CCXI) is $3.74B

What is ChemoCentryx Inc's stock symbol?

The stock symbol (or ticker) of ChemoCentryx Inc is CCXI

How Can Investors Use ChemoCentryx Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of ChemoCentryx Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether ChemoCentryx Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from ChemoCentryx Inc shares for Indian investors?

When investing in ChemoCentryx Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the ChemoCentryx Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare ChemoCentryx Inc share price with other stocks in the same sector?

Rather than merely checking the share price of ChemoCentryx Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that ChemoCentryx Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top